Maravai Lifesciences Holdings, INC Form 4 insider transactions

Kurt Oreshack, General Counsel of Maravai LifeSciences, sold 31,438 shares of Class A Common Stock to cover tax obligations related to vesting restricted stock units.

Christine Dolan, an executive at Maravai LifeSciences, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Peter Leddy, Chief Administrative Officer of Maravai LifeSciences, reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Director R. Andrew Eckert of Maravai LifeSciences Holdings, Inc. acquired 134,409 shares of Class A Common Stock through the vesting of restricted stock units.

Gregory T. Lucier, a director at Maravai LifeSciences, gifted 20,645 shares of Class A Common Stock to a family partnership.

Rebecca Buzzeo, Chief Commercial Officer of Maravai LifeSciences, sold 4,363 shares of Class A Common Stock to cover tax obligations related to vesting restricted stock units.

Director John DeFord of Maravai LifeSciences Holdings, Inc. purchased 17,500 shares of Class A Common Stock at an average price of $5.75.

Maravai LifeSciences' Chief Financial Officer, Kevin Herde, acquired 1,906 shares of Class A Common Stock through the company's Employee Stock Purchase Plan.

Kurt Oreshack, General Counsel of Maravai LifeSciences, acquired 366 shares of Class A Common Stock through the company's Employee Stock Purchase Plan.

Christine Dolan, an Executive Vice President at Maravai LifeSciences, acquired 1,848 shares of Class A Common Stock through the company's Employee Stock Purchase Plan.

Carl Hull, Executive Chairman of Maravai Lifesciences, purchased 175,000 shares of Class A Common Stock at an average price of $5.64.

Andrew Burch, President of Nucleic Acid Production at Maravai LifeSciences, acquired 1,841 shares of Class A Common Stock through the company's Employee Stock Purchase Plan.

William E. Martin, III, CEO of Maravai LifeSciences Holdings, Inc., disposed of 50,843 shares of Class A Common Stock on October 15, 2024, to cover tax obligations related to vesting restricted stock units.

Peter Leddy, Chief Administrative Officer of Maravai LifeSciences, sold shares to cover tax obligations related to vesting restricted stock units.

GTCR Investment XI LLC and affiliated entities, including GTCR funds and Maravai Life Sciences Holdings LLCs, have collectively sold shares of Maravai LifeSciences Holdings, Inc. (MRVI) and exchanged Common Units for Class A common stock.

Director Constantine Mihas reports acquiring 20,645 restricted stock units of Maravai LifeSciences Holdings, Inc.

Director Sean Cunningham reports acquisition of restricted stock units in Maravai LifeSciences, held for the benefit of a GTCR-affiliated entity.

Murali Prahalad, a director at Maravai LifeSciences Holdings, acquired 20,645 shares of Class A Common Stock through restricted stock units on May 23, 2024.

Director Anat Ashkenazi acquired 20,645 shares of Maravai LifeSciences Holdings, Inc. on May 23, 2024.

Director Benjamin Daverman reports acquiring 20,645 Class A Common Stock restricted stock units in Maravai LifeSciences Holdings, Inc.

Director Jessica Hopfield acquired shares and restricted stock units in Maravai LifeSciences Holdings, Inc.

Director Luke Joseph Marker reports acquisition of restricted stock units in Maravai LifeSciences Holdings, Inc.

Director John A. DeFord reports acquisition of Maravai LifeSciences shares and restricted stock units.

Director Susannah Gray reports acquisition of restricted stock units in Maravai LifeSciences Holdings, Inc.

Gregory T. Lucier, a director at Maravai LifeSciences Holdings, Inc., reported acquiring 20,645 shares of Class A Common Stock at $10.78 per share on May 23, 2024, and was granted restricted stock units.

Kurt Oreshack, General Counsel of Maravai LifeSciences Holdings, acquired 341 shares of Class A Common Stock through the company's Employee Stock Purchase Plan on April 30, 2024.

Kevin Herde, CFO of Maravai LifeSciences Holdings, Inc., reports the acquisition of 1,780 shares of Class A Common Stock through the company's Employee Stock Purchase Plan.

Andrew Burch, a Maravai LifeSciences executive, reported acquiring 1,719 shares of Class A Common Stock through the company's Employee Stock Purchase Plan.

Christine Dolan, an executive at Maravai LifeSciences, reported acquiring 483 shares of Class A Common Stock through the company's Employee Stock Purchase Plan.

Peter Michael Leddy, Chief Administrative Officer of Maravai LifeSciences, reports acquiring 4,576 shares of Class A Common Stock through the company's Employee Stock Purchase Plan.